Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 120

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 120
---
 information about our specific intentions for the use of the balance of the net proceeds of this offering. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock. Provisions in our amended and restated certificate of incorporation, as they will be in effect immediately prior to the closing of this offering, and our amended and restated bylaws, as they will be in effect immediately prior to the closing of this offering, may have the effect of delaying or preventing a change of control or changes in our board of directors and management. Our amended and restated certificate of incorporation and amended and restated bylaws will include provisions that:

| • |     | authorize our board of directors to issue, without further action by the stockholders, shares of undesignated                    
 preferred stock with terms, rights, and preferences determined by our board of directors that may be senior to our common stock; |

| • |     | require that any action to be taken by our stockholders be effected at a duly called annual or special meeting 
 and not by written consent;                                                                                    |

| • |     | specify that special meetings of our stockholders can be called only by directors representing a majority of the            
 total authorized size of our board of directors, the chairperson of our board of directors, or our chief executive officer; |

| • |     | establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including 
 proposed nominations of persons for election to our board of directors;                                           |

| • |     | establish that our board of directors is divided into three classes, with each class serving three-year staggered 
 terms;                                                                                                            |

| • |     | prohibit cumulative voting in the election of directors, therefore allowing the holders of a majority of the                                        
 shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose; |

| • |     | provide that our directors may be removed for cause only upon the vote of at least 66 2/3% of our outstanding 
 shares of voting stock;                                                                                       |

|